Bridgeway Capital Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Bridgeway Capital Management’s Portfolio YMAB Stock Details YMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-55,700	Closed	-$251K	–	1292
2025 Q2	$251K	Buy	55,700 +30,800	+124%	+$138K	0.01%	907
2025 Q1	$110K	Sell	24,900 -25,000	-50%	-$145K	﹤0.01%	1022
2024 Q4	$391K	Sell	49,900 -26,100	-34%	-$318K	0.01%	868
2024 Q3	$999K	Hold	76,000	–	–	0.02%	687
2024 Q2	$918K	Buy	76,000 +10,400	+16%	+$140K	0.02%	714
2024 Q1	$1.07M	Sell	65,600 -30,000	-31%	-$404K	0.02%	733
2023 Q4	$652K	Hold	95,600	–	–	0.01%	872
2023 Q3	$521K	Buy	95,600 +20,600	+27%	+$120K	0.01%	862
2023 Q2	$509K	Hold	75,000	–	–	0.01%	892
2023 Q1	$376K	Buy	+75,000	New	+$306K	0.01%	952

Other funds holding YMAB

BIG

Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Bridgeway Capital Management's YMAB Position: Q3 2025 in Review

Bridgeway Capital Management sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 55,700 shares — an estimated $251K sold.

Bridgeway Capital Management first reported a position in YMAB in Q1 2023 and held it in 10 quarters. The position peaked at $1.07M in Q1 2024. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.

Bridgeway Capital Management reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
Bridgeway Capital Management sold 55,700 Y-mAbs Therapeutics shares in Q3 2025, an estimated $251K.
Bridgeway Capital Management first reported a position in Y-mAbs Therapeutics in Q1 2023 and held it in 10 quarters.
Bridgeway Capital Management's Y-mAbs Therapeutics position peaked at $1.07M in Q1 2024.
2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.

Based on Bridgeway Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.